Streetbeat News

Products Services

HTHIY

Hitachi has outperformed 6 out of 7 of the 2023 'Magnificent 7' tech stocks with a 94.9% performance over the past year, driven by its focus on electrification of renewable energy grids. Hitachi's strategic initiatives and $40 billion order backlog position it as a key player in the energy transition.

Portfolio Pulse from

December 08, 2024 | 4:45 am

ABBV

AbbVie announced promising results from a clinical trial of its investigational drug epcoritamab, showing high response rates in patients with relapsed or refractory follicular lymphoma. The data was presented at the American Society of Hematology meeting.

Portfolio Pulse from

December 08, 2024 | 12:15 am

REGN

A Phase 3 trial revealed that the novel combination of Pozelimab and Cemdisiran (Poze-Cemdi) provides better control of intravascular hemolysis in patients with Paroxysmal Nocturnal Hemoglobinuria compared to the standard treatment, Ravulizumab.

Portfolio Pulse from

December 08, 2024 | 12:15 am

O

The article discusses the potential of Realty Income as a stable investment option for building wealth, contrasting it with riskier growth stocks.

Portfolio Pulse from

December 07, 2024 | 11:45 pm

ADPT

Adaptive Biotechnologies presented new data at the 66th ASH Annual Meeting showcasing the effectiveness of their clonoSEQ® MRD testing in influencing treatment decisions for blood cancers such as MCL, CLL, MM, and ALL.

Portfolio Pulse from

December 07, 2024 | 11:45 pm

AFRM

Affirm Holdings, a company offering Buy Now, Pay Later (BNPL) services, may see a positive impact from the recent surge in BNPL usage during Black Friday and Cyber Monday. Consumers used BNPL for nearly a billion dollars in purchases on Cyber Monday, indicating strong demand for such services.

Portfolio Pulse from

December 07, 2024 | 11:30 pm

SNDX

Syndax Pharmaceuticals presented positive data from trials of Revuforj® (revumenib) in acute leukemias at the 66th ASH Annual Meeting. The trials showed high response rates, supporting further development of revumenib in combination therapies.

Portfolio Pulse from

December 07, 2024 | 11:30 pm

ROKU

The article discusses the potential long-term growth of Roku's media-streaming platform, highlighting it as a global business opportunity.

Portfolio Pulse from

December 07, 2024 | 5:00 pm

CRWD

PLTR

The article discusses the potential future valuation of two AI-focused companies, Palantir Technologies and CrowdStrike, predicting that one may surpass the other by 2030. Both companies have been prominent in the AI sector for different reasons.

Portfolio Pulse from

December 07, 2024 | 5:00 pm

META

The potential ban of TikTok could benefit Meta Platforms, Inc. (NASDAQ: META), as its Instagram platform competes directly with TikTok. A ban could lead to increased user engagement and advertising revenue for Instagram.

Portfolio Pulse from

December 07, 2024 | 4:45 pm